EPO and coronary artery disorder: Mazer et al. [19] recently explored the impact of empagliflozin on EPO levels, red blood cell (RBC) morphology, and indices of iron stores in individuals with type 2 diabetes (T2D) and stable coronary artery disease (CAD).